
High-Throughput Mass Spectrometry in Drug Discovery

Edited By Chang Liu and Hui Zhang





High-Throughput Mass Spectrometry in Drug Discovery

High-Throughput Mass Spectrometry in Drug Discovery

Edited by

Chang Liu SCIEX Concord, Canada

Hui Zhang Entos Inc. La Jolla USA



This edition first published 2023 © 2023 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.

The right of Chang Liu and Hui Zhang to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Office John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office 111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data applied for Hardback ISBN: 9781119678434

Cover Design: Wiley Cover Images: Back cover image courtesy of Thomas R. Covey and Ella Potyrala Cover Image: Courtesy of Thomas R. Covey Cover Design Concept: Courtesy of Ella Potyrala

Set in 9.5/12.5pt STIXTwoText by Straive, Pondicherry, India

Contents

List of Contributors xv Preface xix List of Abbreviations xxi

Section 1 Introduction 1

1 Forty-Year Evolution of High-Throughput Mass Spectrometry: A Perspective *3*

Thomas R. Covey

- 1.1 Introduction 3
- 1.2 Ionization Foundations of High-Throughput Mass Spectrometry 5
- 1.2.1 Historical Context of the Development of LC/ MS. Ionization in Vacuum or at Atmospheric Pressure? 7
- 1.2.2 Ambient Sample Introduction Methods (Ambient Ionization) into an API Ion Source Without LC and Their HT-MS Potential 13
- 1.2.3 Direct and Indirect Affinity Measurements with ESI/MS for HTS 16
- 1.3 High-Speed Serial Chromatographic Sample Introduction 18
- 1.3.1 High Flow Rate Ion Sources 19
- 1.3.2 Fast Serial Scheduled, Staggered Chromatographic Separations with Fast Autosamplers 22
- 1.3.3 High-Speed Column Stationary Phases 24
- 1.4 Parallel Chromatographic Sample Introduction 26
- 1.4.1 Overview of Multichannel Indexed Ion Sources 26
- 1.4.2 Fluid Indexing 27
- 1.4.3 Spray Aerosol Indexing 28
- 1.4.4 Ion Beam Indexing 28
- 1.4.5 Ionization Indexing 29
- 1.4.6 Multichannel Autosampler and Pumps 30

٧

- vi Contents
 - 1.5 High Repetition Rate Lasers 32
 - 1.6 Ion Mobility for High-Speed Gas-Phase Separations 35
 - 1.6.1 Motivation and Commercial Options 35
 - 1.6.2 Origins of DMS 36
 - 1.6.3 Chemically Based Selectivity with DMS to Mimic Chromatography *37*
 - 1.7 Mass Spectrometer Sensitivity 40
 - 1.7.1 Historical Gains and Motivation for Sensitivity Improvements 40
 - 1.8 High-Speed Sub-Microliter Volume Sampling 42
 - 1.8.1 Small Sample Size and Low Volume Dispensing HT-MS Technologies 42
 - 1.8.2 Shoot N' Dilute Nanoliter Droplets 44
 - 1.9 Conclusions and Future Prospects 53 References 56

Section 2 LC-MS 75

2 The LeadSampler (LS-1) Sample Delivery System: Integrated Design and Features for High-Efficiency Bioanalysis 77

Brendon Kapinos and John Janiszewski

- 2.1 Introduction 77
- 2.2 Hardware and System Design 80
- 2.3 Software Integration 84
- 2.4 Enabling Emerging Techniques 90
- 2.5 Concluding Remarks 96 References 97

3 Evolution of Multiplexing Technology for High-Throughput LC/MS Analyses 103

Adam Latawiec

- 3.1 Introduction and Historical Developments 103
- 3.2 Developments Toward Fully Integrated Multiplexing Systems 105
- 3.3 Broadening Customer Options 108
- 3.4 Workflow and End-User Considerations 113
- 3.5 Conclusion 115 References 116

Section 3 ESI-MS Without Chromatographic Separation 121

4 Direct Online SPE-MS for High-Throughput Analysis in Drug Discovery 123

Andrew D. Wagner and Wilson Z. Shou

- 4.1 Introduction 123
- 4.2 History of the Development of Direct Online SPE-MS 124
- 4.3 Hardware Details and Data Processing 126
- 4.4 Instrument Performance Highlights 132
- 4.5 Applications 133
- 4.6 Others 134
- 4.7 Future Perspectives 135 References 135
- 5 Acoustic Sampling for Mass Spectrometry: Fundamentals and Applications in High-Throughput Drug Discovery 143 Chang Liu, Lucien Ghislain, Jonathan Wingfield, Sammy Datwani, and Hui Zhang
- 5.1 Introduction 143
- 5.2 Technology Overview 145
- 5.2.1 AMI-MS 145
- 5.2.2 ADE-OPI-MS 151
- 5.2.2.1 System Description 151
- 5.2.2.2 System Tuning and Assay Development 152
- 5.2.2.3 ADE-OPI-MS Automated Data Processing and Automation Integration 154
- 5.3 System Performance 154
- 5.3.1 AMI-MS Performance 154
- 5.3.2 ADE-OPI-MS Performance 160
- 5.4 Applications 162
- 5.4.1 High-Throughput Screening 162
- 5.4.1.1 AMI-MS for HTS 162
- 5.4.1.2 ADE-OPI-MS for HTS 166
- 5.4.2 High-Throughput ADME 168
- 5.4.3 In Situ Reaction Kinetics Monitoring 168
- 5.4.4 Bioanalysis 170

viii Contents

- 5.4.5 Compound QC 171
- 5.4.6 Parallel Medicinal Chemistry 172
- 5.4.7 High-Content Screening 173
- 5.5 Challenges and Limitations 175
- 5.6 Conclusion 176 References 177
- 6 Ion Mobility Spectrometry-Mass Spectrometry for High-Throughput Analysis 183
 - Dylan H. Ross, Aivett Bilbao, Richard D. Smith, and Xueyun Zheng
- 6.1 Introduction of Ion Mobility Spectrometry 183
- 6.2 IMS Fundamental and Experiment 184
- 6.2.1 Ion Mobility Theory 184
- 6.2.2 Collision Cross Section Measurement 186
- 6.2.3 A Typical IMS Experiment 186
- 6.3 IMS Analysis and Applications 187
- 6.3.1 Separation of Isomeric and Isobaric Species by IMS 187
- 6.3.2 High-Throughput IMS Measurements and Building a CCS Library 188
- 6.3.2.1 CCS Measurement of Small Molecules Using DTIMS 190
- 6.3.2.2 CCS Measurements of Drug Compounds Using TWIMS 193
- 6.3.2.3 Large-Scale CCS Databases From Prediction Approaches 195
- 6.3.3 LC-IMS-MS Analysis 195
- 6.3.4 High-Throughput Analysis Using Rapidfire SPE-IMS-MS 196
- 6.3.5 Software Tools for IMS Data Analysis 199
- 6.4 High-Resolution SLIM-IMS Developments 200
- 6.5 Conclusions 204 References 205
- 7 Differential Mobility Spectrometry and Its Application to High-Throughput Analysis 215

Bradley B. Schneider, Leigh Bedford, Chang Liu, Eva Duchoslav, Yang Kang, Subhasish Purkayastha, Aaron Stella, and Thomas R. Covey

- 7.1 Introduction 215
- 7.2 Separation Speed 216
- 7.2.1 Classical Low Field Ion Mobility 216
- 7.2.2 Differential Mobility Spectrometry 217
- 7.2.2.1 FAIMS 218
- 7.2.2.2 DMS 219
- 7.3 Separation Selectivity 220
- 7.3.1 Classical Low Field Ion Mobility 220

- 7.3.2 Differential Mobility Spectrometry 220
- 7.3.2.1 FAIMS 220
- 7.3.2.2 DMS 221
- 7.4 Ultrahigh-Throughput System with DMS 226
- 7.4.1 AEMS Data 231
- 7.4.2 DMS Sensitivity (Ion Transmission) 237
- 7.4.3 Examples of AEMS Analyses with DMS 240
- 7.4.3.1 Example 1. DMS to Eliminate Interferences from Isobaric Species 240
- 7.4.3.2 Example 2. DMS to Eliminate Interferences for Species that are Not Nominally Isobaric 244
- 7.4.3.3 Example 3. DMS to Eliminate Unknown Interferences from Species Endogenous to the Solvent Matrix 250
- 7.4.4 DMS Tuning as a Component of the High-Throughput Workflow 252
- 7.4.5 Automation of the Tuning Process 253
- 7.5 Conclusions 258
- 7.A Chemical Structures 259 References 262

Section 4 Special Sample Arrangement 267

8 Off-Line Affinity Selection Mass Spectrometry and Its Application in Lead Discovery 269 Christopher F. Stratton, Lawrence M. Szewczuk, and Juncai Meng 8.1 Introduction to Off-Line Affinity Selection Mass Spectrometry 269 8.2 Selected Off-Line Affinity Selection Technologies and Its Application in Lead Discovery 270 Membrane Ultrafiltration-Based Affinity Selection 270 8.2.1 8.2.1.1 Introduction of Membrane Ultrafiltration-Based ASMS 270 8.2.1.2 Application of Membrane Ultrafiltration-Based ASMS in Lead Discovery 271 8.2.1.3 Pulse Ultrafiltration-Based ASMS Technology 273 8.2.1.4 Affinity Rank-Ordering Using Pulse Ultrafiltration-Based ASMS 273 8.2.1.5 Advantages and Disadvantages of Membrane Ultrafiltration-Based ASMS 275 8.2.2 Plate-Based Size Exclusion Chromatography 275 Introduction of SpeedScreen: A Plate-Based SEC ASMS 8.2.2.1 Technology 275

x Contents

- 8.2.2.2 Application of SpeedScreen in Lead Discovery 277
- 8.2.2.3 Advantages and Considerations of SpeedScreen 278
- 8.2.3 Bead-Based Affinity Selection 281
- 8.2.3.1 Introduction to Bead-Based Affinity Selection 281
- 8.2.3.2 Application and Discussion of Bead-Based Affinity Selection in Lead Discovery 282
- 8.2.4 Self-Assembled Monolayers and Matrix-Assisted Laser Desorption Ionization (SAMDI) 283
- 8.2.4.1 Introduction to SAMDI Technology 283
- 8.2.4.2 Discussion and Proof-of-Concept of SAMDI Technology for Off-Line ASMS 286
- 8.2.5 Ultracentrifugation Affinity Selection 286
- 8.2.5.1 Introduction to Ultracentrifugation Affinity Selection 286
- 8.2.5.2 Discussion and Proof-of-Concept of Ultracentrifugation Affinity Selection for Off-line ASMS 288
- 8.3 Future Perspectives 291 References 292

9 Online Affinity Selection Mass Spectrometry 297

Hui Zhang and Juncai Meng

- 9.1 Introduction of Online Affinity Selection-Mass Spectrometry 297
- 9.2 Online ASMS Fundamental 299
- 9.3 Instrument Hardware and Software Consideration 300
- 9.3.1 SEC Selection, Fast Separation, and Temperature 300
- 9.3.2 MS: Low Resolution and High Resolution 302
- 9.3.3 Software: Key Features, False Positives, and False Negatives 303
- 9.3.4 Compound Libraries and Compression Level 305
- 9.4 Type of Assays Using ASMS 306
- 9.4.1 Target Identification and Validation 306
- 9.4.2 Hits ID from Combinatorial Libraries or Compound Collections 308
- 9.4.3 Hits Characterization and Leads Optimization 308
- 9.5 Applications Examples and New Modalities of ASMS for Drug Discovery *311*
- 9.6 Future Perspectives 312 References 313

10 Native Mass Spectrometry in Drug Discovery and Development 317 Menavuan lia lianzhona Wen Olivier Mazzicona

Mengxuan Jia, Jianzhong Wen, Olivier Mozziconacci, and Elizabeth Pierson

- 10.1 Introduction 317
- 10.1.1 The Significance of Non-Covalent Protein Complexes in Biology 317

Contents xi

- 10.1.2 Advantages and Disadvantages of Conventional Structural Analytical Techniques *318*
- 10.2 Fundamentals of Native MS *320*
- 10.2.1 Principles of Native Electrospray Ionization 320
- 10.2.2 Specific Sample Preparation to Preserve Non-Covalent Interactions and Be Compatible with ESI-MS Analysis 321
- 10.3 Instrumentation 323
- 10.3.1 Nano-ESI and ESI 323
- 10.3.2 Inline Desalting and Separations Coupled to Native Mass Spectrometry 323
- 10.3.2.1 Inline SEC and Desalting 324
- 10.3.2.2 Inline IEX 325
- 10.3.2.3 Inline HIC 325
- 10.3.2.4 Inline 2D LC 326
- 10.3.2.5 Compatibility with nESI 326
- 10.3.3 High-Throughput Native Mass Spectrometry 327
- 10.3.4 Mass Analyzers 329
- 10.3.5 Data Processing 329
- 10.3.5.1 Contrasts Between Non-Native and Native MS Data Processing and Interpretation 329
- 10.3.5.2 Software for Native MS 330
- 10.4 Application Highlights 330
- 10.4.1 Using Native MS to Develop Stable Protein Formulations 332
- 10.4.2 Native MS to Understand Drug/Target Interaction 334
- 10.4.3 Native Mass Spectrometry and Tractable Protein–Protein Interactions for Drug Discovery 335
- 10.4.4 Structural Stability Using Collision-Induced Unfolding 336
- 10.4.5 Vaccines and Virus Proteins Using CDMS 336
- 10.5 Conclusions and Future Directions 337 References 337

Section 5 Other Ambient Ionization Other than ESI 347

11 Laser Diode Thermal Desorption-Mass Spectrometry (LDTD-MS): Fundamentals and Applications of Sub-Second Analysis in Drug Discovery Environment 349

> *Pierre Picard, Sylvain Letarte, Jonathan Rochon, and Réal E. Paquin* A Historical Perspective of the LDTD *349*

- 11.2 Instrumentation 351
- 11.2.1 LDTD Process 351

11.1

11.2.2 Sample Holder Design 352

xii Contents

- 11.2.3 Vapor Extraction Nozzle 353
- 11.3 Theoretical Background 354
- 11.3.1 Thermal Process 354
- 11.3.2 Gas Dynamics 358
- 11.3.3 Ionization 359
- 11.4 Sample Preparation *362*
- 11.4.1 Motivations 362
- 11.4.2 General Guidelines 362
- 11.4.2.1 Compound Detection Background 363
- 11.4.2.2 Details on Ionic Saturation 364
- 11.4.2.3 Consideration for Biological Matrices 367
- 11.5 Applications 370
- 11.5.1 CYP Inhibition Analysis 371
- 11.5.2 Permeability 373
- 11.5.3 Protein Binding 378
- 11.5.4 Pharmacokinetic 378
- 11.5.5 Preparation Tips 382
- 11.6 Conclusion 384
- 11.6.1 Use and Merits of the Technology 384
- 11.6.2 Limitations 385
- 11.6.3 Perspectives 386 References 387
- 12 Accelerating Drug Discovery with Ultrahigh-Throughput MALDI-TOF MS 393

Sergei Dikler

- 12.1 Introduction 393
- 12.2 uHT-MALDI MS of Assays and Chemical Reactions 396
- 12.2.1 HT-MALDI of Enzymatic Assays 396
- 12.2.2 Screening Chemical Reactions Using uHT-MALDI 401
- 12.2.3 uHT-MALDI of Cell-Based Assays 404
- 12.2.4 uHT-MALDI of Other Types of Assays and Libraries 406
- 12.3 Bead-Based Workflows 408
- 12.4 Using Functionalized, Modified, and Microarrayed MALDI Plates for HT-MALDI *411*
- 12.5 Summary and Future Trends 413 Acknowledgment 414 References 414

13 Development and Applications of DESI-MS in Drug Discovery *423 Wenpeng Zhang*

- 13.1 Introduction 423
- 13.2 Development of DESI and Related Ambient Ionization Methods 424
- 13.3 Applications in Drug Discovery 427
- 13.3.1 Pharmaceutical Analysis and Therapeutic Drug Monitoring 427
- 13.3.2 Analysis of Drugs in Natural Products 428
- 13.3.3 DESI-Based Mass Spectrometry Imaging 430
- 13.3.4 Detection of Drug–Protein Interactions 435
- 13.3.5 High-Throughput Experimentation 438
- 13.3.6 High-Throughput Screening 439
- 13.4 Conclusions and Future Outlook 440 References 442

Section 6 Conclusion 453

- 14The Impact of HT-MS to Date and Its Potential to Shape
the Future of Metrics-Based Experimentation and Analysis455
455Matthew D. Troutman
- 14.1 Defining High-Throughput Mass Spectrometry (HT-MS) 456
- 14.2 HT-MS: Impact to Date 457
- 14.3 Considering How HT-MS Will Shape the Future of Drug Discovery 458 References 462

Index 467

List of Contributors

Leigh Bedford SCIEX, Concord, ON, Canada

Aivett Bilbao Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory Richland, WA, USA

Thomas R. Covey SCIEX, Concord, ON, Canada

Sammy Datwani Beckman Coulter Life Sciences San Jose, CA, USA

Sergei Dikler Bruker Scientific, LLC Billerica, MA, USA

Eva Duchoslav SCIEX, Concord, ON, Canada

Lucien Ghislain Beckman Coulter Life Sciences San Jose, CA, USA John Janiszewski National Center for Advancing Translational Sciences (NCATS) Rockville, MD, USA

Mengxuan Jia Preclinical Development ADMET/BA Merck & Co., Inc South San Francisco, CA, USA

Yang Kang SCIEX, Concord, ON, Canada

Brendon Kapinos Pfizer Worldwide Research and Development, Groton, CT, USA

Adam Latawiec SCIEX, Concord, ON, Canada

Sylvain Letarte R&D Department, Phytronix Technologies Inc., Québec QC, Canada

Chang Liu SCIEX, Concord, ON, Canada xvi List of Contributors

Juncai Meng

Discovery Technology and Molecular Pharmacology (DTMP) Janssen Research & Development LLC, Spring House, PA, USA

Olivier Mozziconacci

Discovery Pharmaceutical Sciences Merck & Co., Inc, South San Francisco CA, USA

Réal E. Paquin

Université Laval Québec, QC, Canada

Pierre Picard R&D Department, Phytronix Technologies Inc., Québec QC, Canada

Elizabeth Pierson Analytical R&D, Merck & Co., Inc., Rahway, NJ, USA

Subhasish Purkayastha SCIEX, Framingham, MA, USA

Jonathan Rochon R&D Department, Phytronix Technologies Inc., Québec, QC, Canada

Dylan H. Ross Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory Richland, WA, USA

Bradley B. Schneider SCIEX, Concord, ON, Canada

Wilson Z. Shou

Lead Discovery and Optimization Bristol-Myers Squibb Company Princeton, NJ, USA

Richard D. Smith

Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory Richland, WA, USA

Aaron Stella SCIEX, Framingham, MA, USA

Christopher F. Stratton

Discovery Technology and Molecular Pharmacology (DTMP), Janssen Research & Development, LLC Spring House, PA, USA

Lawrence M. Szewczuk

Discovery Technology and Molecular Pharmacology (DTMP), Janssen Research & Development, LLC Spring House, PA, USA

Matthew D. Troutman Hit Discovery and Optimization Pfizer, Inc., Groton, CT, USA

Andrew D. Wagner Lead Discovery and Optimization Bristol-Myers Squibb Company Princeton, NJ, USA

Jianzhong Wen Preclinical Development ADMET/BA Merck & Co., Inc South San Francisco, CA, USA

Jonathan Wingfield

Mechanistic and Structural Biophysics Discovery Sciences, R&D AstraZeneca, Cambridge, UK

Hui Zhang

Entos Inc. Department of Analytical Technologies, Entos San Diego, CA, USA

Wenpeng Zhang

State Key Laboratory of Precision Measurement Technology and Instruments, Department of Precision Instrument, Tsinghua University Beijing, China

Xueyun Zheng

Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA

Preface

The automated and integrated high-throughput sample analysis is critical to the drug discovery process. Traditional high-throughput bioanalytical technologies such as colorimetric microplate-based readers are often constrained by linear dynamic range. In addition, they need label attachment schemes with the propensity to modify equilibrium and kinetic analysis. On the other hand, mass spectrometry (MS) based methods can achieve label-free, universal mass detection of a wide arrange of analytes with exceptional sensitivity, selectivity, and specificity. However, these techniques are limited by the speed of sample introduction. In recent decades, there have been a lot of efforts to improve the throughput of MS-based analysis for drug discovery. Along with those developments, a dedicated book would be helpful to introduce the fundamentals, experimental details, and applications of a wide variety of technologies that enabled high-throughput mass spectrometry-based screens in supporting broad drug discovery applications. The key research areas include hit discovery by label-free screen, synthetic reaction optimization, lead optimization and SAR support, ADME (absorption, distribution, metabolism, and excretion), toxicology screening, etc.

This book starts with an overview of the 40 years of efforts to improve the analytical throughput of MS-based approaches (Chapter 1). Then, technologies with highspeed sequential and parallel chromatographic sample introduction, high repetition rate lasers, ion mobility, and low-volume MS samplings were summarized.

Due to its high specificity and high sensitivity, the LC-MS technology has been widely used in various steps of the drug discovery workflow. In Part 2 (Chapter 2–3), the efforts to improve the LC-MS analytical throughput are introduced. The development of the high-speed sample introduction for LC-MS and its application on ADME and HTS applications is described in Chapter 2. Another approach for throughput improvement utilizing paralleled multiplexing LC is described in Chapter 3.

Following the conventional LC-MS-based technologies, other electrospray ionization (ESI)MS-based high-throughput platforms without chromatographic

xx Preface

separation are summarized in Part 3 (Chapter 4–7). Direct online solid-phase extraction (SPE) MS and its application in ADME and HTS workflows are described in Chapter 4. The utilization of the acoustic energy for non-contact transfer samples from microplates to MS for high-throughput analysis, including the acoustic mist ionization (AMI) and through the open-port interface (OPI), is summarized in Chapter 5. By skipping the chromatographic separation process, these approaches demonstrated higher analytical throughput than the conventional LC-MS approach. However, there would be the risk of potential isomeric/isobaric interference. Ion mobility spectrometry (IMS) and differential mobility spectrometry (DMS), described in Chapters 6 and 7, respectively, provide the additional dimension of the selectively, potentially solving the specificity issues of these high-throughput technologies for some drug discovery assays.

Part 4 (Chapters 8–10) summarized the MS-based high-throughput hit identification technologies based on the drug-target interaction. Affinity-selection mass spectrometry (ASMS) is a rapidly developing technology for high-throughput hit identification. The off-line and in-line ASMS approaches are introduced in Chapters 8 and 9. In addition, as a direct confirmation tool for the protein-drug binding, native MS has been rapidly developed in the past decade, which is described in Chapter 10.

Part 5 (Chapter 11–13) introduces developments of ambient ionization technologies other than the conventional ESI and their applications in the high-throughput drug discovery workflows, such as Laser Diode Thermal Desorption (LDTD, Chapter 11), Matrix-Assisted Laser Desorption/Ionization (MALDI, Chapter 12), and Desorption Electrospray Ionization (DESI, Chapter 13).

The last chapter (Chapter 14) provides perspectives for future development opportunities after a brief reflection of the realized impacts of high-throughput MS on drug discovery and the pharmaceutical industry.

We believe our goal in this book is accomplished through the extensive coverage of fundamentals, experimental details, and applications of state-of-art technologies that enable high-throughput MS-based screens in supporting drug discovery. We hope it could benefit scientists in pharmaceutical/biopharmaceutical companies and CROs who design and perform the studies and provide analytical support throughout drug discovery processes. We would like to acknowledge the commitment and contributions of all authors of the book chapters and the support and valuable discussions with colleagues and collaborators in the SCIEX research team and Pfizer Discovery Science department. In addition, we sincerely thank the editorial team at John Wiley & Sons, especially Adalfin Jayasingh, Stacey Woods, Jonathan Rose, Andreas Sendtko, and Sabeen Aziz, for their generous support of this book. Finally, we are grateful to our family members for their understanding and support for our editing work in the evening and on weekends.

List of Abbreviations

| %-RBA | relative binding affinity percentage |
|------------|---|
| μFLC | microflow liquid chromatography |
| 2d | two-dimensional |
| 2-HG | 2-hydroxyglutarate |
| 3CLpro | 3-chymotrypsin-like cysteine protease |
| 4EBP1 | Eukaryotic translation initiation factor 4E-binding protein 1 |
| Α | pre-exponential factor constant |
| ACE50 | affinity competition experiment 50% inhibitory concentration |
| AChE | acetylcholinesterase |
| ADC | antibody—drug conjugate |
| ADE-OPI-MS | acoustic droplet ejection-open port interface-mass |
| | spectrometry |
| ADME | adsorption, distribution, metabolism, and excretion |
| AEMS | acoustic ejection mass spectrometry |
| AMI-MS | acoustic mist ionization-mass spectrometry |
| AMS | affinity mass spectrometry |
| ANSI | American National Standards Institute |
| APCI | atmospheric pressure chemical ionization |
| API | atmospheric pressure ionization |
| APIs | active pharmaceutical ingredients |
| APPI | atmospheric pressure photo ionization |
| ASAP | atmospheric solids analysis probe |
| ASMS | affinity selection mass spectrometry |
| ASMS | American society mass spectrometry |
| Asp | aspartic acid |
| ATD | arrival time distribution |
| ATP | adenosine triphosphate |
| | |

xxii List of Abbreviations

| AUC | analytical ultracentrifugation |
|----------|---|
| AUC | area under the curve |
| BACC | bacterial acetyl coenzyme-A carboxylase |
| BACE | beta-site APP cleaving enzyme |
| BAMS | bead assisted mass spectrometry |
| Bcl-xL | B-cell lymphoma-extra large protein |
| bdf | batch data file |
| BE | buffer exchange |
| Bead-GPS | bead-based global proteomic screening |
| BFA | bound fraction analysis |
| BKM120 | Buparlisib |
| BSA | bovine serum albumin |
| BTE | Boltzmann transport equation |
| C18 | octadecyl stationary phase |
| C8 | octyl stationary phase |
| CCS | collision cross section |
| CD | circular dichroism |
| CDMS | charge detection mass spectrometry |
| CEM | chain ejection model |
| cGAMP | cyclic GMP-ATP |
| cGAS | cyclic GMP-AMP synthase |
| CHCA | α-cyano-4-hyroxycinnamic acid |
| CHK1 | checkpoint kinase |
| CID | collision induced dissociation |
| CIU | collision induced unfolding |
| CN | cyano stationary phase |
| CoV | compensation voltage |
| CPATI | cytosolic proteome and affinity-based target identification |
| CRIMP | Compression Ratio Ion Mobility Programming |
| CRM | charged residue model |
| CV | coefficient of variation |
| CYP | cytochrome P450 |
| Da | Dalton, measurement unit used in mass spectrometry |
| DAR | drug-to-antibody ratio |
| DART | direct analysis in real time |
| DDI | drug–drug interaction |
| DEC | desorption enhancing coating |
| DEL | DNA-encoded library |
| DESI | desorption electrospray ionization |
| DHAP | 2,5-dihydroxyacetophenone |
| DHFR | dihydrofolate reductase |

| diCQA | dicaffeoylquinic acid |
|------------------|--|
| DI-GCE/MS/MS | • • |
| | mass spectrometry |
| DIMS | differential IMS |
| DIOS | desorption ionization on silicon |
| DLS | dynamic light scattering |
| DMA | differential mobility analyzer |
| DMS | differential mobility spectrometry |
| DP | declustering potential |
| DQ | DiscoveryQuant |
| DSF | differential scanning fluorimetry |
| DT | drift time |
| DTIMS | drift tube IMS |
| DUB | deubiquitilase |
| E_{a} | energy of activation |
| ebox | electronics box |
| $E_{\rm d}$ | bound dissociation energy |
| EDTA | ethylenediaminetetraacetic acid |
| EHDI | electrohydrodynamic ionization |
| EI | electron impact |
| EM | electron microscopy |
| ERK1/ERK2 | extracellular signal-regulated kinase 1 and 2 |
| ESI | electrospray ionization |
| ESI-MS | electrospray ionization mass spectrometry |
| E_λ | energy associated with the vibrational wavelength |
| FAB | fast atom bombardment |
| FAIMS | high field asymmetric waveform ion mobility spectrometry |
| FAK | focal adhesion kinase |
| FASN | fatty acid synthase |
| FIA | flow injection analysis |
| FLD | fluorescence detector |
| FP | fluorescence polarization |
| FTE | full-time equivalent |
| FTICR | Fourier-transform ion cyclotron resonance |
| FWHM | full width at half maximum |
| GABA | γ-aminobutyric |
| GC | gas chromatography |
| GLP | good laboratory practice |
| GPC | gel permeation chromatography |
| GST | glutathione S-transferase |
| GWAS | genome-wide association studies |
| | |

xxiv List of Abbreviations

| HBSS | Hank's buffered salt solution |
|-------------|--|
| HCV | hepatitis C virus |
| HDMA | high-density micropatterned array |
| HEPES | 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid |
| HIC | |
| HLM | hydrophobic interaction chromatography human liver microsomes |
| | |
| HMW | high molecular weight species |
| HPLC | high-performance liquid chromatography |
| HRMS | high-resolution mass spectrometry |
| HT-ADME | high-throughput absorption, distribution, metabolism, |
| | excretion |
| HTE | high-throughput experimentation |
| HT-LC/MS/MS | high-throughput mass spectrometry |
| HT-MALDI | high-throughput matrix-assisted laser desorption/ionization |
| HT-MS | high-throughput mass spectrometry |
| HTRF | homogenous time-resolved fluorescence |
| HTS | high-throughput screening |
| IC_{50} | half maximal inhibitory concentration |
| ID | internal diameter |
| IDH1 | isocitrate dehydrogenase 1 |
| IEX | ion exchange chromatography |
| IM | ion mobility |
| IMAC | immobilized metal ion affinity chromatography |
| iMALDI | immuno-matrix-assisted laser desorption/ionization |
| IMS | ion mobility spectrometry |
| IR-MALDESI | infrared matrix-assisted desorption electrospray ionization |
| IS | internal standards |
| isoAsp | isoaspartic acid |
| ITC | isothermal titration calorimetry |
| ITO | indium tin oxide |
| IVIVC | in vitro to in vivo correlations |
| k | rate constant |
| LC | liquid chromatography |
| LC/MS/MS | liquid chromatography tandem mass spectrometry |
| LC-MALDI | liquid chromatography-matrix-assisted laser desorption/ |
| | ionization |
| LC-MS | liquid chromatography mass spectrometry |
| LDLR | low-density lipoprotein receptor |
| LDTD | laser diode thermal desorption |
| LESA | liquid extraction surface analysis |
| LLE | liquid–liquid extraction |
| | 1 1 |

| LOD | limits of detection |
|----------------|--|
| LogD | distribution coefficient |
| LOQ | limit of quantitation |
| LOQ LPS | lipopolysaccharides |
| M3 | microfabricated monolithic multinozzle |
| mAbs | monoclonal antibodies |
| MagMASS | magnetic microbead affinity selection screen |
| MALDI | matrix-assisted laser desorption ionization |
| MALDI-2 | laser-induced postionization |
| MALDI-FTICR MS | matrix-assisted laser desorption/ionization Fourier- |
| | transform ion cyclotron resonance mass spectrometry |
| MALDI-TOF MS | matrix-assisted laser desorption/ionization time-of-flight |
| | mass spectrometry |
| MetAP2 | methionyl aminopeptidase 2 |
| MnESI | microflow-nanospray electrospray ionization |
| MPS | mesoporous silica |
| MRM | multiple reaction monitoring |
| MRO | medical review officer |
| MS | mass spectrometer |
| MS/MS | tandem mass spectrometry |
| MSI | mass spectrometry imaging |
| MTBE | methyl tert-butyl ether |
| MTP | microtiter plate |
| MuRF | muscle RING-finger protein |
| NADPH | nicotinamide adenine dinucleotide phosphate |
| NALDI | nanostructure-assisted laser desorption/ionization |
| Nano-DESI | nanospray desorption electrospray ionization |
| NAPA-LDI | nanopost array-laser desorption/ionization |
| NDM-1 | New Delhi metallo-lactamase1 |
| NDX | native-denatured exchange |
| nESI | nano electrospray ionization |
| NHS | N-hydroxysuccinimide |
| NIMS | nanostructure-initiator mass spectrometry |
| nL | nanoliter |
| NMR | nuclear magnetic resonance |
| nMS | native mass spectrometry |
| NSAID | nonsteroidal anti-inflammatory drugs |
| NSP14 | nonstructural protein 14 |
| OATP2B1 | organic anion transporting polypeptide 2B1 |
| OIMS | overtone IMS |
| OPSI | open port sampling interface |
| | |

xxvi List of Abbreviations

| PAH | polycyclic aromatic hydrocarbon |
|-----------------|---|
| PBED | polybrominated diphenyl ether |
| PBS | phosphate-buffered saline, buffer solution about pH 7.4 |
| PCB | polychlorinated biphenyl |
| PCB | printed circuit board |
| PC-mass-tags | photocleavable mass-tags |
| PFAS | per- and polyfluoroalkyl substances |
| РК | pharmacokinetic |
| pK _a | acid dissociation constant |
| ΡΚCα | protein kinase C-α |
| PMF | peptide mass fingerprinting |
| PoC | percentage of control |
| POE | percent of enrichment |
| PPT | protein precipitation technique |
| PROTAC | proteolysis targeting chimera |
| PTP1B | tyrosine phosphatase 1B |
| PUF-MS | pulsed ultrafiltration-mass spectrometry |
| PVDF | polyvinylidene difluoride |
| QA/QC | quality assurance and quality control |
| qPCR | quantitative polymerase chain reaction |
| qTOF | quadrupole time-of-flight |
| QuEChERS | quick easy cheap effective rugged and safe |
| R | universal gas constant |
| R^2 | coefficient of determination |
| RAM | restricted access media, usually a type of filtering or |
| | extraction media |
| RAM | restricted access medium |
| RF-MS | RapidFire – mass spectrometry |
| ROI | return on investment |
| RXRa | retinoid X receptor-a |
| S/N | signal-to-noise ratio |
| SALLE | salt assisted liquid-liquid extraction |
| SAM | S-adenosyl-L-methionine |
| SAMDI | self-assembled monolayers and matrix-assisted laser |
| | desorption ionization |
| SAR | structure-activity relationship |
| SEC | size-exclusion chromatography |
| SEC-TID | size-exclusion chromatography for target identification |
| SEM | scanning electron microscope |
| SESI | secondary electrospray ionization |

| SEZ | staggered elution zone chromatography |
|-----------|---|
| SIK2 | salt-inducible kinase 2 |
| SIMS | secondary ion mass spectrometry |
| Sirt3 | Sirtuin 3 |
| SISCAPA | stable isotope standards and capture by anti-peptide |
| SISCAIA | antibodies |
| SLIM | structures for lossless ion manipulations |
| SLS | static light scattering |
| SME | small molecular entity |
| SmyD3 | SmyD3 histone methyltransferase |
| SNP | single-nucleotide polymorphism |
| SPE | solid phase extraction |
| SPE-MS | solid-phase extraction mass spectrometry |
| SPME | solid-phase microextraction |
| SPME | * |
| | surface plasmon resonance |
| SRM | selected reaction monitoring |
| SSP | surface sampling probe |
| SUPER | Serpentine Ultralong Path with Extended Routing |
| SV | separation voltage |
| SWATH | sequential window acquisition of all theoretical mass spectra |
| T | absolute temperature in Kelvin |
| ТСР | tumor cell percentage |
| THC | tetrahydrocannabinol |
| TIMS | trapped ion mobility |
| TLC | layer chromatography |
| TMA-lyase | trimethylamine-lyase |
| TM-DESI | transmission mode DESI |
| TM-IMS | transversal modulation IMS |
| TOF | time-of-flight |
| TR-FRET | time-resolved fluorescence energy transfer |
| TRIS | Tris (hydroxymethyl) aminomethane |
| TWIMS | traveling wave ion mobility |
| UFA | unbound fraction analysis |
| UHPLC | ultrahigh-performance (or pressure) liquid chromatography |
| UHPLC/MS | ultrahigh-performance liquid chromatography-mass |
| | spectrometry |
| uHT-MALDI | ultrahigh-throughput matrix-assisted laser desorption/ |
| | ionization |
| uHTS | ultrahigh-throughput screening |
| UPLC | ultra performance liquid chromatography |
| | |

xxviii List of Abbreviations

| UV | ultraviolet, usually meant to describe absorbances between 190 and 400 nm |
|------------------|---|
| UVPD | ultraviolet photodissociation |
| WBA | whole-body autoradiography |
| XRD | X-ray diffraction |
| Δ^9 -THCC | Carboxylic Δ^9 -tetrahydrocannabinol |
| λ | phonon wavelength |